Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts

perjantai 13. marraskuuta 2026 päivittänyt: Liangkai Chen

Effects of Urolithin A on Attention and Circadian Rhythm of Sleep in Healthcare Workers After Night Shifts: An Interventional Study

This pilot study will examine whether taking urolithin A helps healthcare workers stay focused after a night shift. It will also look at changes in fatigue, sleepiness, sleep patterns, and the body's internal clock.

The study plans to enroll 40 physicians and nurses aged 24 to 55 who work scheduled night shifts at Henan Provincial People's Hospital. Participants will be assigned by chance, in equal numbers, to take either 1 gram of urolithin A or a matching placebo capsule by mouth once each morning for five consecutive days, starting the day before the night shift. Participants and the study staff who give out the capsules or assess outcomes will not know which group each participant is in. Participants will follow their usual work schedules.

The main measure is the Stroop interference effect, which is the difference in average response time between correct answers when a color word conflicts with its displayed color and correct answers when they match. The researchers will compare how this measure changes from two days before the night shift to the scheduled follow-up assessments in the two groups.

Participants will also rate their fatigue and sleepiness, wear a wrist device to track sleep, keep a sleep diary, and provide saliva samples to measure melatonin. They will complete tasks that measure alertness and the ability to withhold a response during three MRI scans scheduled before the night shift, on the morning the shift ends, and during recovery. The study will help estimate how much the main measure varies among participants to inform a larger trial.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

This single-center, randomized, double-blind, placebo-controlled pilot trial will be conducted at Henan Provincial People's Hospital. After providing written informed consent and completing baseline assessments, participants will be randomly assigned to a study group. An independent team member who is not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence using SAS version 9.4. Coded study products will be dispensed in enrollment order. Group assignments will be kept confidential until the database is locked, except when emergency unblinding is needed for participant safety.

The day on which the scheduled night shift begins is designated Day 0. Baseline assessments will take place on Day -2. Participants will take their assigned study product each morning from Day -1 through Day 3 and will work their usual scheduled night shift. Computerized Stroop testing will be conducted each morning from Day -2 through Day 4 between 07:00 and 09:00. The final assessment will take place on Day 4, after the dosing period has ended.

Task-based functional MRI will be performed at baseline (Day -2), on the morning the night shift ends (Day 1), and during recovery (Day 3). During each scan, participants will complete an 8-minute Psychomotor Vigilance Task and a 6-minute Go/No-Go task. Stimulus timing and button responses will be recorded and synchronized with image acquisition. Wrist activity recordings will be reviewed alongside sleep diaries to distinguish nighttime sleep from daytime naps and identify periods when the device was removed. Saliva will be collected at scheduled times throughout the observation period, with an additional sample at 03:00 during the night shift. Study staff will record actual sample collection times, review dosing and visit records, and document missed doses, concomitant medication use, and adverse events.

Repeated Stroop interference measurements will be analyzed using a linear mixed-effects model with terms for study group, visit, and their interaction, with adjustment for baseline performance and a participant-level random effect. Estimated between-group differences will be reported with 95% confidence intervals. Exploratory analyses will examine whether changes in task-related brain activity are associated with changes in cognitive performance, fatigue, sleepiness, sleep patterns, and salivary melatonin. Visit completion and adherence data will be used to assess the feasibility of the study procedures for a larger trial.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

40

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Haoxiang Xu
  • Puhelinnumero: 0371-65580020
  • Sähköposti: xhx0227@163.com

Opiskelupaikat

    • Henan
      • Zhengzhou, Henan, Kiina, 450003
        • Henan Provincial People's Hospital
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
          • Liangkai Chen, PhD
          • Puhelinnumero: 0371-65580020
          • Sähköposti: clk@hust.edu.cn
        • Alatutkija:
          • Haoxiang Xu, Currently pursuing a master's

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

24 vuotta - 55 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Aged 24 to 55 years, inclusive.
  • Physicians or nurses who work scheduled night shifts.
  • No history of neurological or psychiatric disorders.
  • No diagnosed sleep disorder.
  • No contraindications to magnetic resonance imaging (MRI).
  • Right-handed.

Exclusion Criteria:

  • Recent use of sleep aids or psychoactive medications.
  • Severe sleep disruption outside periods of shift work.
  • Gastrointestinal disease that may affect urolithin A absorption.
  • Pregnancy or breastfeeding.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Muut
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Urolithin A

Participants will take 1 g of urolithin A(StanYouth™️ Urolithin A) in capsule form by mouth once daily between 07:00 and 09:00 for five consecutive days, from the day before the scheduled night shift (Day -1) through Day 3.

Oral urolithin A(StanYouth™️ Urolithin A) capsules at a total daily dose of 1 g. The capsules are taken once each morning between 07:00 and 09:00 for five consecutive days, beginning the day before the scheduled night shift (Day -1) and continuing through Day 3.

Placebo Comparator: Matching Placebo

Participants will take 1 g of matching placebo capsules by mouth once daily between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. The placebo capsules contain no urolithin A and match the urolithin A capsules in appearance, color, and packaging.

Oral placebo capsules containing no urolithin A and matching the urolithin A capsules in appearance, color, and packaging. The capsules are taken at a total daily dose of 1 g, once each morning between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change From Baseline in the Stroop Reaction Time Interference Effect
Aikaikkuna: Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

At each assessment, the Stroop reaction time interference effect is calculated by subtracting the mean reaction time for valid correct responses in congruent trials from the mean reaction time for valid correct responses in incongruent trials. Reaction times are measured in milliseconds. Change from baseline is calculated as the interference effect at each follow-up assessment minus the baseline interference effect. A positive change indicates greater interference than at baseline.

Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Stroop Reaction Time by Trial Condition,Stroop Response Accuracy by Trial Condition
Aikaikkuna: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4

Mean reaction time, in milliseconds, for valid correct responses on the computerized Stroop task, reported separately for congruent and incongruent trials.

Percentage of trials with a correct response on the computerized Stroop task, reported separately for congruent and incongruent trials.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
Psychomotor Vigilance Task
Aikaikkuna: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for valid responses. Premature responses and omissions are excluded.

Number of responses with a reaction time of at least 500 milliseconds within the 10-second response window.

Number of slow responses divided by [prespecified denominator], multiplied by 100.

Number of presented targets for which no response is recorded within 10 seconds.

Number of omitted responses divided by[ prespecified denominator], multiplied by 100.

Number of premature responses, defined as button presses during the waiting interval or responses occurring less than 100 milliseconds after target onset.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Go/No-Go Trial
Aikaikkuna: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Mean reaction time, in milliseconds, for correct responses on Go trials. Percentage of presented Go trials with a valid button press within the response window.

Percentage of presented Go trials without a valid button press within the response window.

Percentage of presented No-Go trials with a button press within the response window.

Percentage of presented No-Go trials without a button press within the response window.

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Visual Analog Scale for Fatigue Score
Aikaikkuna: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Participants rate their current fatigue on a 100-mm visual analog scale. Scores range from 0 mm (no fatigue) to 100 mm (extreme fatigue), with higher scores indicating greater fatigue.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Karolinska Sleepiness Scale Score
Aikaikkuna: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.

Self-rated sleepiness measured on the 9-point Karolinska Sleepiness Scale. Scores range from 1 to 9, with higher scores indicating greater sleepiness.

Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
Fatigue Severity Scale Score
Aikaikkuna: Baseline (Day -2) and final follow-up (Day 4).

The 9-item Fatigue Severity Scale assesses the impact of fatigue on daily functioning over the past week. Each item is scored from 1 to 7. Item scores are summed to give a total score ranging from 9 to 63, with higher scores indicating a greater impact of fatigue.

Baseline (Day -2) and final follow-up (Day 4).
Salivary Melatonin Concentration
Aikaikkuna: From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.

Melatonin concentration measured in saliva samples collected at scheduled times and reported in [laboratory reporting unit].

From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
Actigraphy-Derived Sleep Parameters
Aikaikkuna: Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).

Total time spent asleep during the recorded sleep episode, estimated from wrist actigraphy and reported in minutes.

Percentage of time in bed spent asleep, estimated from wrist actigraphy. Time from attempting to fall asleep to estimated sleep onset, reported in minutes.

Total time spent awake after initial sleep onset and before final awakening, estimated from wrist actigraphy and reported in minutes.

Number of awakenings detected by wrist actigraphy after initial sleep onset and before final awakening.

Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
Task-Evoked Brain Activation During the Psychomotor Vigilance Task
Aikaikkuna: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Psychomotor Vigilance Task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
Task-Evoked Brain Activation During the Go/No-Go Task
Aikaikkuna: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Task-evoked brain activation during the Go/No-Go task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis].

Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Jie Wang, PhD, Henan Provincial People's Hospital
  • Opintojohtaja: Liangkai Chen, PhD, Huazhong University of Science and Technology
  • Opintojohtaja: Yongli Li, PhD, Henan Provincial People's Hospital
  • Opintojohtaja: Zhengqian Li, PhD, Peking University Third Hospital
  • Päätutkija: Haoxiang Xu, Currently pursuing a master's, Henan Provincial People's Hospital

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 16. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. helmikuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 1. helmikuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 13. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 19. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 19. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

IPD-suunnitelman kuvaus

The scope, timing, and access procedures for sharing individual participant data are under consideration. Any future sharing would be limited to de-identified data made available to qualified researchers or research institutions for scientific purposes, subject to ethics committee requirements and applicable regulations.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa